SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) Short Interest Up 22.1% in December

SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) was the recipient of a significant increase in short interest during the month of December. As of December 31st, there was short interest totaling 49,429,420 shares, an increase of 22.1% from the December 15th total of 40,466,622 shares. Currently, 35.1% of the shares of the stock are short sold. Based on an average daily trading volume, of 11,457,774 shares, the short-interest ratio is presently 4.3 days. Based on an average daily trading volume, of 11,457,774 shares, the short-interest ratio is presently 4.3 days. Currently, 35.1% of the shares of the stock are short sold.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of SELLAS Life Sciences Group in a research note on Wednesday, October 8th. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $7.00.

SELLAS Life Sciences Group Trading Up 4.0%

SLS traded up $0.16 during trading hours on Monday, hitting $4.00. The company’s stock had a trading volume of 7,832,575 shares, compared to its average volume of 13,529,520. The stock has a market cap of $569.05 million, a price-to-earnings ratio of -14.27 and a beta of 2.26. The business’s 50-day moving average price is $2.49 and its 200-day moving average price is $2.05. SELLAS Life Sciences Group has a 12 month low of $0.85 and a 12 month high of $5.18.

SELLAS Life Sciences Group (NASDAQ:SLS) last released its quarterly earnings data on Wednesday, November 12th. The company reported ($0.06) EPS for the quarter, beating the consensus estimate of ($0.08) by $0.02. On average, analysts forecast that SELLAS Life Sciences Group will post -0.57 earnings per share for the current year.

Insider Activity at SELLAS Life Sciences Group

In related news, Director Katherine Bach Kalin bought 63,400 shares of the company’s stock in a transaction that occurred on Wednesday, November 19th. The stock was purchased at an average price of $1.59 per share, for a total transaction of $100,806.00. Following the completion of the transaction, the director owned 104,400 shares in the company, valued at $165,996. The trade was a 154.63% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is available through this hyperlink. Company insiders own 1.40% of the company’s stock.

Institutional Investors Weigh In On SELLAS Life Sciences Group

Several large investors have recently added to or reduced their stakes in SLS. Bank of America Corp DE lifted its stake in shares of SELLAS Life Sciences Group by 21.9% in the 3rd quarter. Bank of America Corp DE now owns 42,150 shares of the company’s stock valued at $68,000 after purchasing an additional 7,571 shares during the last quarter. BNP Paribas Financial Markets lifted its stake in SELLAS Life Sciences Group by 89.2% in the third quarter. BNP Paribas Financial Markets now owns 19,724 shares of the company’s stock worth $32,000 after purchasing an additional 9,299 shares during the last quarter. Opus Capital Group LLC boosted its position in shares of SELLAS Life Sciences Group by 4.2% during the third quarter. Opus Capital Group LLC now owns 250,000 shares of the company’s stock valued at $403,000 after buying an additional 10,000 shares during the period. Equitable Holdings Inc. grew its stake in shares of SELLAS Life Sciences Group by 58.6% during the third quarter. Equitable Holdings Inc. now owns 27,060 shares of the company’s stock valued at $44,000 after buying an additional 10,000 shares during the last quarter. Finally, Axxcess Wealth Management LLC purchased a new stake in shares of SELLAS Life Sciences Group in the third quarter worth approximately $26,000. 17.38% of the stock is owned by institutional investors.

SELLAS Life Sciences Group Company Profile

SELLAS Life Sciences Group, Inc is a clinical-stage biopharmaceutical company focused on the development of active cellular immunotherapies for cancer. Headquartered in Waltham, Massachusetts, SELLAS specializes in targeting the Wilms’ tumor 1 (WT1) antigen, a protein commonly overexpressed in a range of hematologic and solid tumors. Since its founding, the company has built a pipeline around the use of peptide-based vaccines designed to train the patient’s own immune system to recognize and attack WT1-positive cancer cells.

The company’s lead product candidate, galinpepimut-S (GPS), is an investigational multi-peptide vaccine directed against WT1.